Xin Lang Cai Jing·2025-10-27 07:13Core Insights - Novartis has signed a strategic cooperation agreement with Kangzhe Weisheng, a wholly-owned subsidiary of Kangzhe Pharmaceutical, for the exclusive import, commercial promotion, and distribution rights of two ophthalmic products in China starting from November 1, 2025 [1] - The agreement is set for a duration of five years, indicating a long-term partnership between the companies [1] - This strategic agreement aligns with Novartis' global "focus" strategy, concentrating on four core therapeutic areas: cardiovascular, renal and metabolic, oncology, and immunology and neuroscience [1] Company Summary - Novartis will transfer the rights for its ophthalmic products, Nofiz (Ranibizumab injection) and Beiyoushi (Brolucizumab injection), to Kangzhe Weisheng [1] - The partnership aims to enhance resource integration and provide innovative drugs with high clinical value to patients [1]